Latest Dabigatran Stories

The Rottenstein Law Group, a Pradaxa law firm, acknowledges that the FDA has conducted extensive research into the topic, but the firm is still actively monitoring reports of side effects and filing lawsuits on behalf of clients who believe that Pradaxa injured them. (PRWEB) March 15, 2013 Although there have been numerous Pradaxa lawsuits because of the anticoagulant drug’s alleged excessive bleeding side effects, the U.S. Food and Drug Administration issued a report* this week...

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com New York, NY (PRWEB) March 12, 2013 The drug safety advocates at DrugRisk.com are alerting those patients taking the blood thinner Pradaxa of new information on the site showing the manufacturer, Boehringer Ingelheim, is testing an antidote for internal bleeding, as the number of bleeding injury claims has risen substantially...

Recently, the law firm of d’Oliveira & Associates, has announced a “No Win, No Fee Promise” to any clients that have suffered any of the side effects of Xarelto and may be entitled to compensation. (PRWEB) March 12, 2013 Xarelto is an anticoagulant that is manufactured by the Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Approved by The U.S. Food and Drug Administration in just 2011, the drug was intended to act as a blood thinner to help prevent blood clots and...

New Infographic released by d’Oliveira & Associates details potential Side Effects, Company Reports, and Independent Medical Studies that surround the drug meant to prevent blood clots in patients. (PRWEB) March 11, 2013 d’Oliveira & Associates has posted a new infographic to its website detailing the side effects and the elevated risks of bleeding associated with using the anticoagulant drug Pradaxa. As reported by the FDA, common side effects of the drug may include...

In response to increasing numbers of inquiries from concerned consumers, Resource4thePeople announces free consultations to evaluate allegations from patients who may have suffered alleged internal bleeding health problems from Pradaxa blood thinner medication. San Diego, CA (PRWEB) March 09, 2013 http://www.resource4thepeople.com/defectivedrugs/pradaxa-lawsuits.html Resource4thePeople announced today that its attorneys are now investigating claims from victims who allegedly may have...

d'Oliveira & Associates releases new webpages and infographic On Pradaxa lawsuits. (PRWEB) March 06, 2013 Manufactured by Boehringer Ingelheim, Pradaxa is an anticoagulant drug that is used to treat a variety of blood and heart conditions*. In October 2010, the Food and Drug Administration (FDA) approved Pradaxa for sale on the market*. As reported by the NY Times, Pradaxa was marketed as a superior drug choice to Warfarin, but medical studies suggest that Pradaxa may be more...

RIDGEFIELD, Conn., March 5, 2013 /PRNewswire/ -- Boehringer Ingelheim will present data on dabigatran from four abstracts at the 62(nd) Annual Scientific Session of the American College of Cardiology (ACC) in San Francisco, Calif., from March 9 to 11, 2013. Detailed information regarding the data presentations include: Saturday, March 9, Poster Sessions Effect of Dabigatran on Serum Apo-Lipoprotein B and Apo-Lipoprotein A1 Concentrations (Lead Author: P. Joseph) [Abstract No....

The Firm is currently investigating Pradaxa lawsuits on behalf of individuals who suffered life-threatening internal bleeding, allegedly due to Pradaxa. New York, New York (PRWEB) March 03, 2013 Pradaxa lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court documents, the next Status Conference in the Pradaxa litigation has been scheduled for March 14, 2013....

Website Tells Story of Support and Engagement to Provide More Health RIDGEFIELD, Conn, Feb. 25, 2013 /PRNewswire/ -- Boehringer Ingelheim Cares Foundation today announced that it has published its first online Giving Report, which is available at http://givingreport.us.boehringer-ingelheim.com. The Giving Report summarizes through short stories, pictures and videos the four primary ways the Foundation makes more health: the donation of our medicine, our support of and engagement in...

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDY(SM) and RE-SONATE(®), show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine. VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and...